Wave Life Sciences Q3 net loss widens 15% to $61.91 million; Q3 revenue rises 73% to $13.16 million

Bitget2026/10/27 11:32

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Wave Life Sciences’ third-quarter 2026 net loss widened 15% year over year to $61.91 million.
Revenue climbed 73% year over year to $13.16 million.
Cash, cash equivalents and marketable securities totaled $431 million at September 30, with operations funded into the third quarter of 2028.
Planning is underway for WVE-006’s two-year AATD registrational trial, including a one-year interim analysis supporting potential accelerated approval.
The WVE-007 combination trial with tirzepatide is underway, with a post-incretin maintenance trial targeted to begin in the fourth quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wave Life Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610270730PRIMZONEFULLFEED9853687) on October 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Wave Life Sciences Q3 net loss widens 15% to $61.91 million; Q3 revenue rises 73% to $13.16 million

You may also like

Crypto prices